INDICATION AND IMPORTANT SAFETY INFORMATION
Vivotif® (Typhoid vaccine live oral attenuated Ty21a) is indicated for immunization of adults and children against disease caused by Salmonella typhi (new nomenclature: Salmonella enterica subspecies enterica serovar Typhi). Results from clinical studies indicate that adults and children 5 years and older may be protected against typhoid fever following the oral ingestion of 4 doses of Vivotif® (enteric-coated capsules). Immunization (ingestion of all 4 capsules) should be completed at least 1 week prior to exposure to S. typhi (see DOSAGE AND ADMINISTRATION).
TAKE4 is a NEW program offered by EMERGENT® to help travellers remember to complete their 4-dose course of VIVOTIF prior to their trip. To enroll in the TAKE4 text reminder program, travelers text "TRAVEL" to 1-450-400-0015 on the day of their first dose. They will receive a text every other day reminding them to take their next dose and to refrigerate the remaining capsules.*†
*See Product Monograph for full dosing, administration, and storage instructions.
*The information requested will be used by EMERGENT to send text message reminders. Message and data rates may apply. This is a recurring program that includes a number of messages over the course of 7 days. At any time during the program, travellers may text “HELP” for assistance or “STOP” to discontinue receiving messages.
INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR VIVOTIF®
INDICATIONS AND CLINICAL USE
Vivotif® (Typhoid vaccine live oral attenuated Ty21a) is indicated for immunization of adults
and children against disease caused by Salmonella typhi (new nomenclature: Salmonella
enterica subspecies enterica serovar Typhi). Results from clinical studies indicate that adults
and children 5 years and older may be protected against typhoid fever following the oral
ingestion of 4 doses of Vivotif® (enteric-coated capsules). Immunization (ingestion of all 4
capsules) should be completed at least 1 week prior to exposure to S. typhi (see DOSAGE
AND ADMINISTRATION).
Routine typhoid vaccination is not recommended in Canada but immunization should be
considered in the following situations:
1) Travel in endemic areas for extended periods, or off the usual tourist tracks;
2) On-going household or intimate exposure to a typhoid carrier;
3) Laboratory workers who frequently handle cultures of S. typhi.
Not all recipients of Vivotif® will be fully protected against typhoid fever. Travellers should take all necessary precautions to avoid contact with or ingestion of potentially contaminated food or water.
There is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps.
Vivotif® will not afford protection against enteric organisms other than S. typhi.
There are no studies reported using Vivotif® as a booster for persons previously vaccinated with the parenteral vaccine.
An optimal booster dose has not yet been established. However, it is recommended that a booster dose consisting of 4 capsules taken on alternate days be given every 7 years under conditions of repeated or continued exposure to typhoid fever (see DOSAGE AND ADMINISTRATION).
Typhoid fever continues to be an important disease in many parts of the world. Travellers entering such areas are at risk of contracting typhoid fever following the ingestion of contaminated food or water.
There are no data in geriatrics. The efficacy of Vivotif® (enteric-coated capsules) has not been established in children under 5 years of age. The capsule formulation is therefore not recommended for use in children under 5 years of age.
RELEVANT WARNINGS AND PRECAUTIONS
CONTRAINDICATIONS
Safety of the vaccine has not been demonstrated in persons deficient in their ability to
mount a humoral or cell-mediated immune response due to either a congenital or acquired
immunodeficient state, including treatment with immunosuppressive or antimitotic drugs. The
vaccine should not be administered to these persons regardless of benefits.
ADVERSE REACTIONS
The most common adverse reactions in clinical trials disappeared spontaneously within a
few days and included: abdominal pain, nausea, diarrhoea, vomiting, fever, headache, rash.
No serious adverse systemic reactions were reported.
FOR MORE INFORMATION
Please consult the Vivotif Product Monograph for more information on the clinical use,
contraindications, warnings, precautions, adverse reactions, drug interactions, and
dosing instructions.